IMI Stakeholder Forum 2017 - Open innovation

Start Date 18/10/2017 End Date 19/10/2017
Brussels, Belgium

The IMI Stakeholder Forum 2018 took place on Wednesday 18 and Thursday 19 October 2017 at the Hotel Crowne Plaza Le Palace, Brussels. 

 

18 October
Open innovation |  Agenda 

On the first day of the Stakeholder Forum we looked at IMI through the lens of open innovation, and discussed the results that the partnership is delivering through a dynamic, multi-stakeholder, collaborative innovation ecosystem. 


Keynote: Iain Gillespie | Pro-Vice-Chancellor Research and Enterprise at the University of Leicester 
Presentation
Video recording

Discussion, moderated by Pierre Meulien:

  • Iain Gillespie
  • Nathalie Moll | Director General, European Federation of Pharmaceutical Industries and Associations (EFPIA)
  • Kurt Vandenberghe  | Director Policy Development and Coordination, DG Research and Innovation, European Commission 

Video recording

Chantal Mathieu | Professor of Medicine and Program Director of Biomedical Sciences at the Katholieke Universiteit Leuven | IMI INNODIA project
Presentation
Video recording

Emilio Merlo Pich | Head, Quantitative Medicine & Partnering, CNS Therapeutic Area, Vice-President, Takeda
Presentation
Video recording

Aled Edwards | Director and CEO of the Structural Genomics Consortium (SGC), Professor at the University of Toronto and Visiting Professor at the University of Oxford | IMI ULTRA-DD project
Presentation
Video recording

Topics to be launched under IMI2 - Call 13
Hugh Laverty,  Head of Science Operations, Innovative Medicines Initiative (IMI)
Presentation 
Video recording

Think Big  | IMI pipeline 2018-2020
Salah-Dine Chibout, Global Head Discovery & Investigative Safety, Novartis
Presentation
Video recording

 

19 October
Patient Forum | Agenda 

In IMI’s public-private open innovation model, patients are the ultimate recipients of IMI’s R&D efforts, and an invaluable partner in research. This event, co-developed by IMI and the European Patients’ Forum (EPF) set out discussions on how to achieve real and meaningful patient engagement, how to measure and demonstrate its value, and how to secure willingness to collaborate. The goal of the event was to further the discussion on what are the most meaningful models of patient collaboration in order for patients’ voices to be heard.
This track was chaired by Tamsin Rose | Director, Progress Works.

Keynote: Nicola Bedlington | Secretary General, European Patient Forum
Video recording

Patient involvement  | Return on engagement

Dominique Hamerlijnck  | EUPATI fellow, patient advocate at the Dutch Lung Foundation
Presentation
Video recording

Discussion:

  • Jacqueline Broerse | Research Director of the Faculty of Sciences; Full professor of innovation and communication; Director of the Athena Institute (FALW), Vrije Universisiteit Amsterdam
  • Magda Chlebus | Director Science Policy, EFPIA
  • Julian Isla | Founder and Chairman of the Dravet Syndrome Foundation | President of the Dravet Syndrome European Federation
  • Lucia Monaco  |  Chief Scientific Officer, Telethon Foundation
  • Sue Pavitt | Professor of Translational & Applied Health Research at the University of Leeds
  • Eileen Penman | Member of the EPAD Research Participant Panel

Video recording

Patient outcome perspective on big data & digital health: what role for patients?

The IMI Big Data for Better Outcome Programme | Patricia van Dijck | Director Healthcare System Solutions, Novartis Oncology Europe; IMI Harmony project
Presentation

Discussion:

  • Juan Garcia Burgos |  Head of Public Engagement, Stakeholders and Communications, European Medicines Agency (EMA)
  • Ilaria Passarani | Head of Food and Health, BEUC
  • Patricia van Dijck | Novartis 
  • Spyros Zorbas | Member of the patient advisory group of the IMI RADAR-CNS project

Video recording

Redefining patient engagement: innovative models of collaboration

Discussion:

  • Olivier Arnaud |  Senior Director, European Research, JDRF International
  • Annette Bakker |  President and Chief Scientific Officer, Children's Tumour Foundation
  • James Cusack | Director of Research, Autistica
  • Matthias Gottwald | Head R&D Policy and Networking, Bayer
  • Lee Wen Hwa  | Director, Oxford Martin Programme on Affordable Medicines at the University of Oxford; Director, Disease Foundations Network, Strategic Alliances at the Structural Genomics Consortium; IMI ULTRA-DD project

Video recording

 

19 October
Microbiome forum |​ Agenda 

The microbiome has come under the spotlight in recent years for its potential to be a turning point in medical research. The challenges it entails, however, require breakthrough collaboration between a diverse range of leading health stakeholders, from both the private and public sectors. This event brought together the pharmaceutical, food / feed and diagnostics industries for an open and dynamic discussion with medtechs, regulators, researchers and other players on the needs for and benefits of collaborative research in the microbiome field.

Keynote: Human microbiome in health & disease
Dusko Ehlrich 
| International Human Microbiome Consortium
Presentation | coming soon
Video recording | coming soon

Regulatory challenges in the drug-food continuum

Yolanda Sanz | Professor of Research Microbial Ecology, Nutrition & Health Research Unit, Institute of Agrochemistry and Food Technology (IATA), National Research Council (CSIC), Spain 
Presentation
Video recording

Nino Mihokovic |  Quality Specialist, European Medicines Agency
Presentation
Video recording

Q&A chaired by Maria Beatriz Da Silva Lima, Chair of the IMI Scientific Committee, Professor of Pharmacology and Pharmatoxicology, University of Lisbon
Video recording

Stakeholder discussion |  The potential of collaborative research: accelerating breakthroughs and reducing fragmentation in microbiome research
  • Frank Møller Aarestrup | Global Microbial Indentifier
  • Antoine Coutant | Managing Director, Savencia Ingredients and Nutritional Solutions
  • Wulf Fischer-Knuppertz | CEO & Chairman, Biocrates Life Sciences
  • Marco Greco | President of the European Patients’ Forum (EPF), Past Chairman of the European Federation of Crohn’s and Ulcerative Colitis Associations (EFCCA)
  • Dirk Hadrich | Scientific Officer, DG Research & Innovation, European Commission
  • Kristof Van Emelen | CSO – Product Development, ProDigest
  • Vijay Yajnik | Medical Director, Clinical Science, GI TAU, Takeda

Video recording

Themes under consideration for potential microbiome topics under an IMI Call for proposals

Large longitudinal studies with open access to metadata
Stefan J. Scherer 
| VP Global Head Correlative Science, Novartis Pharmaceuticals Corporation
Presentation
Video recording

Bio-informatics solutions for strain level identification and analysis of hypothetical genes
Alain Pluquet 
| Corporate VP, Chief Data Officer, bioMerieux
Presentation
Video recording

Bio-banks of identifiable species with metadata, reference methods and standards
Alain Pluquet 
| Corporate VP, Chief Data Officer, bioMerieux
Presentation
Video recording

Translational studies addressing microbiome causality in human health and disease
James R. Brown
, presented by Graham Somers, IMI Portfolio Director, GSK
Presentation
Video recording

 

Conclusions

Summary & conclusions from the Patient Forum
Catherine Brett, External Relations Manager, Innovative Medicines Initiative (IMI)
Presentation
Video recording

Summary & conclusions from the Microbiome Forum
Elisabetta Vaudano, Principal Scientific Manager,  Innovative Medicines Initiative (IMI)
Presentation
Video recording

Anders Olauson | Honorary President, European Patient Forum
Video recording

 

Stay up to date

To stay up to date with our events, sign up to our newsletter, join our LinkedIn group, or follow us on Twitter at @IMI_JU. If you have any questions or suggestions for next year's Stakeholder Forum, do not hesitate to contact us.